Tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and platinum-based chemotherapy with or without pemetrexed in patients with NSQ NSCLC

Trial Identifier: ACT16146
Sponsor: Sanofi
Start Date: October 2020
Primary Completion Date: March 2024
Study Completion Date: December 2024
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
BRAZIL, Rio Grande do Norte Natal, Rio Grande do Norte, BRAZIL, 59062-000
Chile Santiago, Chile, 7500713
Chile Santiago, Chile, 8241470
Chile, La Araucanía Temuco, La Araucanía, Chile, 4780000
Chile, Valparaíso Viña del Mar, Valparaíso, Chile, 2520598
Czechia Olomouc, Czechia, 77900
Czechia Ostrava - Vitkovice, Czechia, 70384
France Avignon, France, 84918
France Brest, France, 29200
France Pessac, France, 33600
France Poitiers Cedex, France, 86021
Hungary Budapest, Hungary, 1122
Hungary Farkasgyepü, Hungary, 8582
ISRAEL Ramat Gan, ISRAEL, 5266202
ISRAEL Tel Aviv, ISRAEL, 64239
SPAIN, A Coruña [La Coruña] La Coruña, A Coruña [La Coruña], SPAIN, 15006
SPAIN, Asturias Oviedo, Asturias, SPAIN, 33011
SPAIN, Catalunya [Cataluña] Badalona, Catalunya [Cataluña], SPAIN, 08916
SPAIN, Las Palmas Las Palmas, SPAIN, 35016
SPAIN, Madrid Madrid, SPAIN, 28040
SPAIN, Madrid Madrid, SPAIN, 28041
United States, Kansas Westwood, Kansas, United States, 66205